Derms on Drugs

Episodes

• 
  The Hills Are Alive With New Targets 06.11.2026 28m

  The Derms stay in Vienna for round two of EADV, where zombie-cell cream meets new pathways in HS and AD—plus a JAK surprise in PPP and reassuring pregnancy data.
• 
  Better Croissants, Stranger Drugs 30.10.2026 33m

  EADV serves up better croissants—and a packed menu of new mechanisms. The Derms dig into injectable RNA for BCC, a possible anti-scarring angle in HS, a TYK2 showdown, and an alopecia treatment that may keep working after treatment ends.
• 
  The Fast and the Urticarious 27.10.2026 23m

  Dr. Jason Hawkes makes the case for putting speed first when choosing an advanced treatment for CSU. Remibrutinib works fast—but can he convince the Derms that fast is reason enough to put it first?
• 
  High D, Low Certainty 23.10.2026 32m

  The Derms size up high-dose vitamin D, a head-to-head lichen planus trial, and whether contact dermatitis testing is overcalling the culprit.
• 
  Custom Shots and Drug Cocktails 16.10.2026 29m

  The Derms question treatment monogamy: a personalized melanoma vaccine joins forces with immunotherapy, while dual therapy takes on refractory HS and AD.
• 
  AI Crosses the Prescription Line 09.10.2026 37m

  In Utah, AI is getting its hands on the prescription pad—starting with topical acne treatment. The Derms grill Nolla’s CEO on the big questions: Who catches the misses, and is this better access or the beginning of the robot takeover?
• 
  The Goldilocks Biologic 05.10.2026 16m

  Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, and insurance all enter the argument.
• 
  Tiny Vesicles, Big Claims 02.10.2026 37m

  Exosomes may be real science, but the marketing has sprinted miles ahead of the data. The Derms dig into their promise for burns and epidermolysis bullosa—and why that pricey cosmetic vial may not contain what it claims.
• 
  Cuts, Switches, and Eight Extra Hairs 25.09.2026 27m

  Three papers, three practical questions: Who really needs antibiotics before derm surgery? What comes after an AD drug fails? And does taking oral minoxidil in the morning actually grow more hair—or just raise more eyebrows?
• 
  Blood, Sweat, and Hives 22.09.2026 18m

  Dr. Marc Serota makes the case for targeted lab testing in CSU—but the Derms worry it may open a can of worms. The Chronic Urticaria Index gets a closer look, shotgun allergy panels get nowhere—but does he convince the Derms?
• 
  Paging Dr. Telederm 18.09.2026 38m

  After 70,000 virtual consults, Dr. Joe English knows what a photo can—and can’t—tell you. He joins the Derms to talk diagnostic curveballs, hospital saves, and bringing dermatology where there’s no dermatologist in sight.
• 
  Tregs, Tape, and Tresses 11.09.2026 28m

  Three papers, three very different reactions: a Treg-boosting AD drug that may be too clever for its own good, a Steri-Strip trick you can use tomorrow, and Rinvoq alopecia data that have the Derms calling game changer.
• 
  Don’t Wait for the Tunnels 08.09.2026 18m

  Convince the Derms on Drugs makes its debut with Dr. Christopher Sayed making the case for earlier systemic treatment in HS. Can he convince the Derms to act before recurring lesions become tunnels, scars, and damage no medication can undo?
• 
  Patch Me If You Can 04.09.2026 29m

  Patch first or treat first? The Hamann brothers join the Derms to tackle mystery dermatitis, questionable allergens, wet wraps, hand eczema—and why the answer may be hiding in your patient’s shampoo.
• 
  The Clot Thickens 28.08.2026 33m

  Three papers, three plot twists: new HS data that underwhelm on paper, a transected melanoma that may not need a sentinel node, and a possible explanation for why JAK clot risk may depend on the disease.
• 
  The Long and Short of Male Genital Disease 21.08.2026 41m

  Male genital disease expert Dr. Christopher Bunker joins the Derms for the penis episode no one else was brave enough to make. Lichen sclerosus, circumcision, penile cancer—and one diagnosis he says doesn’t exist—are all on the table.
• 
  Three Sheets to Tofa 14.08.2026 32m

  The Derms debut a shorter format with three papers and one newly dirt-cheap drug: generic tofacitinib. The safety, the risks, and the practicalities—right down to getting it for just $25 a month.
• 
  Creams, Screams, and Measles 07.08.2026 47m

  Pediatric dermatology legend Dr. Sheila Fallon Friedlander joins the Derms to sort through the new topical “Goldilocks” problem, take the sting out of Dupixent injections, and make the case for treating molluscum sooner. Plus, how to recognize measles—and why its most frightening complication may not appear for years.
• 
  Can We Stop Referring CSU? 31.07.2026 26m

  The CSU rulebook is getting a rewrite, and the Derms on Drugs crew has thoughts. Dr. Jason Hawkes joins the conversation to talk new guidelines, new therapies, and why it may be time to stop sending these patients somewhere else.
• 
  The Gray Zone Strikes Again 24.07.2026 46m

  This week, the DoD tackle studies that leave plenty of room for debate—from skin cancer treatment costs and melanoma risk to HS, alopecia areata, and the real-world decisions that don't always come with straightforward answers.